Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

July 12, 2019 8:47 PM UTC

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a differentiated patient population following the approval of two other new therapies this year.

MediciNova Inc. (NASDAQ:MNOV; Tokyo:4875) gained $1.32 (15%) to $10.42 on NASDAQ Friday, adding about $56 million in market cap, after revealing its plans...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Medicinova Inc.